CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Con Stough; Madeleine Nankivell; David A. Camfield; Naomi L. Perry; Andrew Pipingas; Helen Macpherson; Keith Wesnes; Keith Wesnes; Keith Wesnes; Ruchong Ou; David Hare; Judy de Haan; Geoffrey Head; Peter Lansjoen; Alena Langsjoen; Brendan Tan; Matthew P. Pase; Matthew P. Pase; Matthew P. Pase; Rebecca King; Renee Rowsell; Oliver Zwalf; Yossi Rathner; Matthew Cooke; Franklin Rosenfeldt; Franklin Rosenfeldt

doi:10.3389/fnagi.2019.00103

Frontiers in Aging Neuroscience (May 2019)

CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly

Con Stough,
Madeleine Nankivell,
David A. Camfield,
Naomi L. Perry,
Andrew Pipingas,
Helen Macpherson,
Keith Wesnes,
Keith Wesnes,
Keith Wesnes,
Ruchong Ou,
David Hare,
Judy de Haan,
Geoffrey Head,
Peter Lansjoen,
Alena Langsjoen,
Brendan Tan,
Matthew P. Pase,
Matthew P. Pase,
Matthew P. Pase,
Rebecca King,
Renee Rowsell,
Oliver Zwalf,
Yossi Rathner,
Matthew Cooke,
Franklin Rosenfeldt,
Franklin Rosenfeldt

Affiliations

Con Stough: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Madeleine Nankivell: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
David A. Camfield: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Naomi L. Perry: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Andrew Pipingas: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Helen Macpherson: Faculty of Health, Institute for Physical Activity and Nutrition, Deakin University, Geelong, VIC, Australia
Keith Wesnes: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Keith Wesnes: Wesnes Cognition Limited, Streatley on Thames, United Kingdom
Keith Wesnes: Department of Psychology, Northumbria University, Newcastle, United Kingdom
Ruchong Ou: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
David Hare: Austin Hospital, University of Melbourne, Melbourne, VIC, Australia
Judy de Haan: Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
Geoffrey Head: Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
Peter Lansjoen: East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, United States
Alena Langsjoen: East Texas Medical Center and Trinity Mother Francis Hospital, Tyler, TX, United States
Brendan Tan: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Matthew P. Pase: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Matthew P. Pase: Melbourne Dementia Research Centre, The Florey Institute for Neuroscience and Mental Health, Melbourne, VIC, Australia
Matthew P. Pase: Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia
Rebecca King: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Renee Rowsell: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Oliver Zwalf: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Yossi Rathner: 0Department of Health and Medical Sciences, Swinburne University of Technology, Melbourne, VIC, Australia
Matthew Cooke: 0Department of Health and Medical Sciences, Swinburne University of Technology, Melbourne, VIC, Australia
Franklin Rosenfeldt: Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia
Franklin Rosenfeldt: Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

DOI: https://doi.org/10.3389/fnagi.2019.00103
Journal volume & issue: Vol. 11

Abstract

Read online

Introduction: With an aging population there is an important need for the development of effective treatments for the amelioration of cognitive decline. Multiple mechanisms underlie age-related cognitive decline including cerebrovascular disease, oxidative stress, reduced antioxidant capacity and mitochondrial dysfunction. CoQ10 is a novel treatment which has the potential to improve brain function in healthy elderly populations due to established beneficial effects on mitochondrial function, vascular function and oxidative stress.Methods and Analysis: We describe the protocol for a 90-day randomized controlled trial which examines the efficacy of Ubiquinol (200 mg/day) vs. placebo for the amelioration of cognitive decline in a healthy (non-demented) elderly sample, aged 60 years and over. The primary outcome is the effect of Ubiquinol at 90 days compared to baseline on CogTrack composite measures of cognition. Additional cognitive measures, as well as measures of cardiovascular function, oxidative stress, liver function and mood will also be monitored across 30-, 60- and 90- day time points. Data analyses will involve repeated measures analysis of variance (ANOVA).Discussion: This study will be the first of its kind to provide important clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive decline in the healthy elderly with important implications for productivity and quality of life within this age group.Clinical Trial Registration: The trial has been registered with the Australian and New Zealand Clinical Trials Registry (ANZCTRN12618001841268).

Published in Frontiers in Aging Neuroscience

ISSN: 1663-4365 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.frontiersin.org/journals/aging-neuroscience

About the journal

Abstract

Keywords